[go: up one dir, main page]

HUP0102812A3 - Pharmaceutical compositions containing the phospholipase inhibitor sodium {[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1h-indol-4-yl]oxy}acetate and process for pruducing them - Google Patents

Pharmaceutical compositions containing the phospholipase inhibitor sodium {[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1h-indol-4-yl]oxy}acetate and process for pruducing them

Info

Publication number
HUP0102812A3
HUP0102812A3 HU0102812A HUP0102812A HUP0102812A3 HU P0102812 A3 HUP0102812 A3 HU P0102812A3 HU 0102812 A HU0102812 A HU 0102812A HU P0102812 A HUP0102812 A HU P0102812A HU P0102812 A3 HUP0102812 A3 HU P0102812A3
Authority
HU
Hungary
Prior art keywords
pruducing
dioxoethyl
phenylmethyl
indol
oxy
Prior art date
Application number
HU0102812A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HUP0102812A2 publication Critical patent/HUP0102812A2/hu
Publication of HUP0102812A3 publication Critical patent/HUP0102812A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HU0102812A 1998-03-03 1999-03-02 Pharmaceutical compositions containing the phospholipase inhibitor sodium {[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1h-indol-4-yl]oxy}acetate and process for pruducing them HUP0102812A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7665998P 1998-03-03 1998-03-03
PCT/US1999/004516 WO1999044604A1 (en) 1998-03-03 1999-03-02 Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate

Publications (2)

Publication Number Publication Date
HUP0102812A2 HUP0102812A2 (hu) 2001-12-28
HUP0102812A3 true HUP0102812A3 (en) 2002-01-28

Family

ID=22133426

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102812A HUP0102812A3 (en) 1998-03-03 1999-03-02 Pharmaceutical compositions containing the phospholipase inhibitor sodium {[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1h-indol-4-yl]oxy}acetate and process for pruducing them

Country Status (21)

Country Link
US (1) US6166062A (hu)
EP (1) EP1058547B1 (hu)
JP (3) JP2002505282A (hu)
KR (1) KR20010034552A (hu)
CN (1) CN1299277A (hu)
AT (1) ATE310513T1 (hu)
AU (1) AU757002B2 (hu)
BR (1) BR9908479A (hu)
CA (1) CA2322796A1 (hu)
DE (1) DE69928500T2 (hu)
EA (1) EA003864B1 (hu)
ES (1) ES2253877T3 (hu)
HU (1) HUP0102812A3 (hu)
ID (1) ID27487A (hu)
IL (1) IL138154A0 (hu)
NO (1) NO20004306L (hu)
NZ (1) NZ506578A (hu)
PL (1) PL342822A1 (hu)
TR (1) TR200002543T2 (hu)
TW (1) TW570795B (hu)
WO (1) WO1999044604A1 (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055108A2 (en) * 2000-01-25 2001-08-02 Eli Lilly And Company Use of spl a2 inhibitors for the treatment of inflammation
AU2001229252A1 (en) * 2000-03-09 2001-09-17 Eli Lilly And Company Method for the treatment of renal dysfunction with spla2 inhibitors
JP2004503586A (ja) * 2000-07-14 2004-02-05 イーライ・リリー・アンド・カンパニー 敗血症の治療方法
TWI232102B (en) 2001-07-17 2005-05-11 Shionogi & Co A pharmaceutical formulation for injection
CN1568999A (zh) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
MXPA06012777A (es) * 2004-05-06 2007-02-14 Cydex Inc Formulaciones de sabor enmascarado que contienen sertralina y eter sulfoalquilico-ciclodextrina.
WO2007141298A1 (en) * 2006-06-09 2007-12-13 Schwarz Pharma Ag Stabilized pharmaceutical compositions comprising fesoterodine
CN101674734A (zh) * 2007-02-12 2010-03-17 拉萨德·布杰贝尔 不含防腐剂的无菌三氯蔗糖溶液
JP5174365B2 (ja) * 2007-03-23 2013-04-03 第一三共株式会社 キノロン含有凍結乾燥製剤の製造方法
EP2106788A1 (en) * 2008-04-04 2009-10-07 Ipsen Pharma Liquid and freeze dried formulations
US9884019B2 (en) 2008-08-05 2018-02-06 Wyeth Llc Lyophilization above collapse
WO2010127099A2 (en) 2009-04-29 2010-11-04 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2013032184A2 (ko) * 2011-08-26 2013-03-07 제이더블유중외제약 주식회사 피라지노-트리아진 유도체를 포함하는 조성물
EP2923710A1 (en) 2014-03-27 2015-09-30 Universitätsklinikum Heidelberg Bacterial phospholipase inhibitors as modulator of colonic bacterial flora

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO873860L (no) * 1986-10-31 1988-05-02 Asta Pharma Ag Ifosfamid-lyofilisat og fremgangsmaate til deres fremstilling.
JPH02207092A (ja) * 1989-02-07 1990-08-16 Kirin Brewery Co Ltd アンスラサイクリン化合物またはその塩の凍結乾燥製剤の製造法
CN1060042C (zh) * 1993-10-27 2001-01-03 法玛西雅厄普约翰美国公司 稳定的前列腺素e1
PT675110E (pt) * 1994-04-01 2002-11-29 Lilly Co Eli 1h-indole-3-glioxilamidas inibidoras da spla2

Also Published As

Publication number Publication date
DE69928500T2 (de) 2006-08-03
AU2799899A (en) 1999-09-20
EA003864B1 (ru) 2003-10-30
WO1999044604A1 (en) 1999-09-10
JP2006096761A (ja) 2006-04-13
ATE310513T1 (de) 2005-12-15
JP2011021042A (ja) 2011-02-03
TR200002543T2 (tr) 2000-11-21
CA2322796A1 (en) 1999-09-10
CN1299277A (zh) 2001-06-13
US6166062A (en) 2000-12-26
BR9908479A (pt) 2000-12-05
KR20010034552A (ko) 2001-04-25
EP1058547B1 (en) 2005-11-23
TW570795B (en) 2004-01-11
NZ506578A (en) 2003-09-26
NO20004306L (no) 2000-10-10
HUP0102812A2 (hu) 2001-12-28
JP2002505282A (ja) 2002-02-19
PL342822A1 (en) 2001-07-02
EA200000897A1 (ru) 2001-02-26
EP1058547A1 (en) 2000-12-13
NO20004306D0 (no) 2000-08-29
WO1999044604A9 (en) 2000-01-20
DE69928500D1 (de) 2005-12-29
IL138154A0 (en) 2001-10-31
ID27487A (id) 2001-04-12
AU757002B2 (en) 2003-01-30
ES2253877T3 (es) 2006-06-01

Similar Documents

Publication Publication Date Title
HUP0100156A3 (en) Indole derivatives as inhibitors of phospholipase a2 and use of them for producing pharmaceutical compositions
IS1940B (is) Lyfjasamsetningar sem innihalda HMG afoxunarensímlata
HUP0102812A3 (en) Pharmaceutical compositions containing the phospholipase inhibitor sodium {[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1h-indol-4-yl]oxy}acetate and process for pruducing them
HUP0101146A3 (en) Indole derivatives as inhibitors of phospholipase enzymes and pharmaceutical compositions containing them
HUP0100757A3 (en) Indole derivatives as inhibitors of phospholipase enzymes and pharmaceutical compositions containing them
HUP0004120A3 (en) Use of cgmp-pde5 inhibitors for the preparation of pharmaceutical compositions treating neuropathy
HUP0104987A2 (hu) Benzimidazol- és indolszármazék proteáz inhibitorok és ezeket tartalmazó gyógyszerkészítmények
ZA200108082B (en) Pharmaceutical compositions comprising dipeptidy peptidase IV inhibitors for the promotion of growth.
HUP0302485A3 (en) Arylmethylamine derivatives for use as tryptase inhibitors and pharmaceutical compositions containing them
HUP0203122A3 (en) Fab i inhibitors, process for their preparation, pharmaceutical compositions containing them and their use
HUP0103452A3 (en) Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors and pharmaceutical compositions containing the compounds
HUP0303146A3 (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors and pharmaceutical compositions containing them
AU1928501A (en) Formulations for pharmaceutical agents ionizable as free acids or free bases
HUP0200124A3 (en) Phenyl- and pyridinyl derivatives, process for their preparation and pharmaceutical compositions containing them
IL143979A0 (en) Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
ZA973647B (en) Inhibitors of metalloprotease, process for preparing them and pharmaceutical compositions containing them.
HUP0102922A2 (hu) 2,3-Szubsztituált indolszármazékok mint COX-2 inhibitorok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
HUP0204157A3 (en) 1,3-dihydro-2h-indol-2-one derivatives, process for preparation of the compounds and pharmaceutical compositions containing the same
AU7079700A (en) Improved stable formulations of ace inhibitors, and methods for preparation thereof
EP1133230A4 (en) DOSAGE FORMULAS FOR ACETYLCHOLINESTERASE INHIBITORS
HUP0203597A3 (en) Pharmaceutical compositions containing zolmitriptan, process for their preparation and their use
HUP0204585A3 (en) Ox(adi)azolyl-hydroxamic acids useful as procollagen c-proteinase inhibitors, process for their preparation and pharmaceutical compositions containing them
HUP9801950A3 (en) 2-(arylphenyl-amino)-imidazoline derivatives, process for producing them and pharmaceutical compositions containing them
GB0031145D0 (en) Compounds that effect cd83 expression pharmaceutical compositions comprising said compounds and methods for identifying said compounds
HUP0105282A3 (en) Acetylenic sulfonamide thiol tace inhibitors process for their preparation and pharmaceutical compositions containing the same